Comparison between single dose and multiple dose Rituximab in idiopathic membranous nephropathy
Not Applicable
- Conditions
- Health Condition 1: N042- Nephrotic syndrome with diffuse membranous glomerulonephritis
- Registration Number
- CTRI/2020/11/029094
- Lead Sponsor
- RS Medical College and Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. biopsy proven membranous nephropathy
2. serologically anti PLA2R antibody positive
3. patients eligible for treatment as per standard protocol
4. patients who are willing to give consent
Exclusion Criteria
1. presence of active sepsis
2. pregnancy
3. active malignancy
4. co-infection with HIV / Hep B / Hep C
5. prior treatment with any immunosuppressant therapy
6. presence of heart failure
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cumulative number of patients who will experience both partial and complete remissionTimepoint: 6 months
- Secondary Outcome Measures
Name Time Method 1. eGFR at the completion of therapy <br/ ><br>2. Change in serum albumin level <br/ ><br>3. Change in lipid profile <br/ ><br>4. Time required for complete or partial remission <br/ ><br>5. Adverse effectsTimepoint: 6 months